| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 3 securities · may seek to influence control | ||||||
|
Celcuity Inc.
13D/A
CELC · 15102K100
|
4.9% |
3/9/2026
Event 3/5/2026
|
||||
| Growth Equity Opportunities 18 VGE, LLC | 4.9% | |||||
| NEA 18 Venture Growth Equity, L.P. | 4.9% | |||||
| NEA Partners 18 VGE, L.P. | 4.9% | |||||
| Nea 18 Vge GP, LLC | 4.9% | |||||
| Ali Behbahani | 4.9% | |||||
| Carmen Chang | 4.9% | |||||
| Anthony A. Florence, Jr. | 4.9% | |||||
| Mohamad H. Makhzoumi | 4.9% | |||||
| Edward T. Mathers | 4.9% | |||||
| Scott D. Sandell | 4.9% | |||||
| Paul Walker | 4.9% | |||||
| Rick Yang | 4.9% | |||||
|
Gossamer Bio, Inc.
13D/A
GOSS · 38341P102
|
1.7% |
2/24/2026
Event 2/23/2026
|
||||
| Growth Equity Opportunities 18 VGE, LLC | 1.7% | |||||
| NEA 18 Venture Growth Equity, L.P. | 1.7% | |||||
| NEA Partners 18 VGE, L.P. | 1.7% | |||||
| Nea 18 Vge GP, LLC | 1.7% | |||||
| Ali Behbahani | 1.7% | |||||
| Carmen Chang | 1.7% | |||||
| Anthony A. Florence, Jr. | 1.7% | |||||
| Mohamad H. Makhzoumi | 1.7% | |||||
| Edward T. Mathers | 1.7% | |||||
| Scott D. Sandell | 1.7% | |||||
| Paul Walker | 1.7% | |||||
| Rick Yang | 1.7% | |||||
|
X4 Pharmaceuticals, Inc.
13D/A
XFOR · 98420X202
|
6.2% |
10/29/2025
Event 10/27/2025
|
||||
| Growth Equity Opportunities 18 VGE, LLC | 6.2% | |||||
| NEA 18 Venture Growth Equity, L.P. | 6.2% | |||||
| NEA Partners 18 VGE, L.P. | 6.2% | |||||
| Nea 18 Vge GP, LLC | 6.2% | |||||
| Ali Behbahani | 6.2% | |||||
| Carmen Chang | 6.2% | |||||
| Anthony A. Florence, Jr. | 6.2% | |||||
| Mohamad H. Makhzoumi | 6.2% | |||||
| Edward T. Mathers | 6.2% | |||||
| Scott D. Sandell | 6.2% | |||||
| Paul Walker | 6.2% | |||||
| Rick Yang | 6.2% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.